NCT07242417 2026-01-21
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
Beijing GoBroad Hospital
Phase EARLY_PHASE1 Recruiting
Clinical Trials
12 trialsNCT07246304 2025-11-24
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07059975 2025-11-04
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
Phase EARLY_PHASE1 Recruiting
NCT06092047 2025-05-16
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06532630 2025-02-28
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT06756321 2025-01-03
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
Phase EARLY_PHASE1 Recruiting
NCT06652243 2024-11-25
SN301A
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT06696833 2024-11-20
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT05141474 2024-11-07
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
Phase EARLY_PHASE1 Recruiting
NCT04561557 2024-10-30
CARTinNS
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT06532643 2024-09-19
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting